Systemic inflammation contributes to acute decompensated heart failure. Atibuclimab (IC14) is a monoclonal antibody blocking CD14, an inflammatory mediator associated with adverse cardiovascular outcomes. In this phase Ib, open-label, single-arm trial, adults ... ...

请注册登录后继续浏览